233 related articles for article (PubMed ID: 28548087)
1. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
3. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
[TBL] [Abstract][Full Text] [Related]
4. Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC).
Piper AJ; Clark JL; Mercado-Matos J; Matthew-Onabanjo AN; Hsieh CC; Akalin A; Shaw LM
PLoS One; 2019; 14(8):e0220567. PubMed ID: 31393907
[TBL] [Abstract][Full Text] [Related]
5. Progress and prospects of early detection in lung cancer.
Blandin Knight S; Crosbie PA; Balata H; Chudziak J; Hussell T; Dive C
Open Biol; 2017 Sep; 7(9):. PubMed ID: 28878044
[TBL] [Abstract][Full Text] [Related]
6. Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets.
Pazhouhandeh M; Samiee F; Boniadi T; Khedmat AF; Vahedi E; Mirdamadi M; Sigari N; Siadat SD; Vaziri F; Fateh A; Ajorloo F; Tafsiri E; Ghanei M; Mahboudi F; Rahimi Jamnani F
Sci Rep; 2017 Oct; 7(1):13812. PubMed ID: 29062084
[TBL] [Abstract][Full Text] [Related]
7. Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth.
Contat C; Ancey PB; Zangger N; Sabatino S; Pascual J; Escrig S; Jensen L; Goepfert C; Lanz B; Lepore M; Gruetter R; Rossier A; Berezowska S; Neppl C; Zlobec I; Clerc-Rosset S; Knott GW; Rathmell JC; Abel ED; Meibom A; Meylan E
Elife; 2020 Jun; 9():. PubMed ID: 32571479
[TBL] [Abstract][Full Text] [Related]
8. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
9. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.
Hsieh MH; Choe JH; Gadhvi J; Kim YJ; Arguez MA; Palmer M; Gerold H; Nowak C; Do H; Mazambani S; Knighton JK; Cha M; Goodwin J; Kang MK; Jeong JY; Lee SY; Faubert B; Xuan Z; Abel ED; Scafoglio C; Shackelford DB; Minna JD; Singh PK; Shulaev V; Bleris L; Hoyt K; Kim J; Inoue M; DeBerardinis RJ; Kim TH; Kim JW
Cell Rep; 2019 Aug; 28(7):1860-1878.e9. PubMed ID: 31412252
[TBL] [Abstract][Full Text] [Related]
10. Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells.
Aldonza MBD; Son YS; Sung HJ; Ahn JM; Choi YJ; Kim YI; Cho S; Cho JY
Oncotarget; 2017 Jun; 8(26):42817-42835. PubMed ID: 28467805
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma.
Qin N; Li Y; Wang C; Zhu M; Dai J; Hong T; Albanes D; Lam S; Tardon A; Chen C; Goodman G; Bojesen SE; Landi MT; Johansson M; Risch A; Wichmann HE; Bickeboller H; Rennert G; Arnold S; Brennan P; Field JK; Shete S; Le Marchand L; Melander O; Brunnstrom H; Liu G; Hung RJ; Andrew A; Kiemeney LA; Zienolddiny S; Grankvist K; Johansson M; Caporaso N; Woll P; Lazarus P; Schabath MB; Aldrich MC; Stevens VL; Jin G; Christiani DC; Hu Z; Amos CI; Ma H; Shen H
Front Med; 2021 Apr; 15(2):275-291. PubMed ID: 32889700
[TBL] [Abstract][Full Text] [Related]
12. Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer.
Luengo A; Abbott KL; Davidson SM; Hosios AM; Faubert B; Chan SH; Freinkman E; Zacharias LG; Mathews TP; Clish CB; DeBerardinis RJ; Lewis CA; Vander Heiden MG
Nat Commun; 2019 Dec; 10(1):5604. PubMed ID: 31811141
[TBL] [Abstract][Full Text] [Related]
13. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer.
De Zuani M; Xue H; Park JS; Dentro SC; Seferbekova Z; Tessier J; Curras-Alonso S; Hadjipanayis A; Athanasiadis EI; Gerstung M; Bayraktar O; Cvejic A
Nat Commun; 2024 May; 15(1):4388. PubMed ID: 38782901
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka Y; Nakai T; Suzuki A; Kagawa Y; Noritake O; Taki T; Hashimoto H; Sakai T; Shibata Y; Izumi H; Nosaki K; Udagawa H; Zenke Y; Matsumoto S; Yoh K; Miyazaki S; Sakamoto N; Sakashita S; Kojima M; Watanbe R; Tsuboi M; Goto K; Ishii G
Cancer Immunol Immunother; 2023 Jul; 72(7):2205-2215. PubMed ID: 36862151
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.
Lou TF; Sethuraman D; Dospoy P; Srivastva P; Kim HS; Kim J; Ma X; Chen PH; Huffman KE; Frink RE; Larsen JE; Lewis C; Um SW; Kim DH; Ahn JM; DeBerardinis RJ; White MA; Minna JD; Yoo H
Cancer Prev Res (Phila); 2016 Jan; 9(1):43-52. PubMed ID: 26511490
[TBL] [Abstract][Full Text] [Related]
16. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.
Wu D; Pang Y; Wilkerson MD; Wang D; Hammerman PS; Liu JS
Br J Cancer; 2013 Sep; 109(6):1599-608. PubMed ID: 24002593
[TBL] [Abstract][Full Text] [Related]
17. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression.
Shi Y; Fan S; Wu M; Zuo Z; Li X; Jiang L; Shen Q; Xu P; Zeng L; Zhou Y; Huang Y; Yang Z; Zhou J; Gao J; Zhou H; Xu S; Ji H; Shi P; Wu DD; Yang C; Chen Y
Nat Commun; 2019 Oct; 10(1):4892. PubMed ID: 31653849
[TBL] [Abstract][Full Text] [Related]
18. Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer.
Khayati K; Bhatt V; Lan T; Alogaili F; Wang W; Lopez E; Hu ZS; Gokhale S; Cassidy L; Narita M; Xie P; White E; Guo JY
Cancer Res; 2022 Dec; 82(23):4429-4443. PubMed ID: 36156071
[TBL] [Abstract][Full Text] [Related]
19. Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.
Kind M; Klukowska-Rötzler J; Berezowska S; Arcaro A; Charles RP
PLoS One; 2017; 12(10):e0187308. PubMed ID: 29088297
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Aquaporin 5 Expression in Non-small Cell Lung Cancer.
Jo YM; Park TI; Lee HY; Jeong JY; Lee WK
J Pathol Transl Med; 2016 Mar; 50(2):122-8. PubMed ID: 26863575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
